Renaissance Technologies LLC boosted its position in shares of OvaScience Inc (NASDAQ:OVAS) by 61.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,062,768 shares of the biotechnology company’s stock after purchasing an additional 405,800 shares during the period. Renaissance Technologies LLC’s holdings in OvaScience were worth $964,000 at the end of the most recent reporting period.
Separately, Wells Fargo & Company MN increased its holdings in OvaScience by 217.6% during the 1st quarter. Wells Fargo & Company MN now owns 473,876 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 324,685 shares in the last quarter. 20.56% of the stock is owned by institutional investors.
OVAS stock opened at $0.79 on Friday. OvaScience Inc has a 1 year low of $0.66 and a 1 year high of $1.60.
OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter. OvaScience had a negative return on equity of 47.19% and a negative net margin of 11,175.59%. The firm had revenue of $0.08 million for the quarter.
Separately, ValuEngine upgraded OvaScience from a “hold” rating to a “buy” rating in a report on Thursday.
OvaScience, Inc, a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility.
Featured Article: Initial Public Offering (IPO)
Want to see what other hedge funds are holding OVAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OvaScience Inc (NASDAQ:OVAS).
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.